Current landscape of innovative drug development and regulatory support in China by Ruirong Tan, Hua Hua, Siyuan Zhou, Zhimin Yang, Changming Yang, Guo Huang, Jin Zeng, Junning Zhao

Get full text

IP6K2 mutations as a novel mechanism of resistance to oncolytic virus therapy by Zhijian Huang, Xiangqian Zhao, Zirong Jiang, Xiaoting Qiu, Xinhao Sun, Dawei Wang, Hucheng Zhang, Qi Chen, Ruirong Tan, Yangkun Shen

Get full text

Correction: Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates by Yu-Ying Shi, Gang Fan, Ruirong Tan, Shan Li, Hua-Bing Sun, Rui Li, Mengni Yang, Shanshan Gao, Miao Liu, Meng-Yuan Dai

Get full text

Treating ICB-resistant cancer by inhibiting PD-L1 via DHHC3 degradation induced by cell penetrating peptide-induced chimera conjugates by Yu-Ying Shi, Gang Fan, Ruirong Tan, Shan Li, Hua-Bing Sun, Rui Li, Mengni Yang, Shanshan Gao, Miao Liu, Meng-Yuan Dai

Get full text

Overview of pharmacodynamical research of traditional Chinese medicine on hyperuricemic nephropathy: from the perspective of dual-regulatory effect on the intestines and kidneys by Ting Wang, Ting Wang, Li Li, Li Liu, Ruirong Tan, Qinxuan Wu, Xin Zhu, Hua Hua, Ying Dai, Huan Li, Jiuzhou Mao, Junning Zhao, Junning Zhao, Zhujun Yin, Zhujun Yin

Get full text